Partnering Agreements in Diagnostics

Partnering Agreements in Diagnostics

Summary

The Partnering Agreements in Diagnostics report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.
- Comprehensive directory of diagnostic deals since 2003
- Diagnostic contract documents
- Diagnostic agreement terms
- Diagnostic agreement structure
- Top diagnostic deals by value
- Most active diagnostic dealmakers

Description

The Partnering Agreements in Diagnostics report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains over 500 links to online copies of actual diagnostic contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of diagnostic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of diagnostic dealmaking since 2000. The chapter includes numerous case studies to enable understanding of diagnostic dealmaking.
Chapter 3 provides an overview of the trends in diagnostic dealmaking since 2000.
Chapter 4 provides a review of the leading diagnostic deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of diagnostic contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of diagnostic partnering deals signed and announced since 2003, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in diagnostic partnering and dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostic technologies and products.

Key benefits

Partnering Agreements in Diagnostics provides the reader with the following key benefits:
- In-depth understanding of diagnostic deal trends since 2000
- Analysis of the structure of diagnostic agreements with numerous real life case studies
- Comprehensive access to over 500 actual diagnostic contracts entered into by the world’s biopharma companies
- Detailed access to actual diagnostic contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a diagnostic agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Agreements in Diagnostics is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.
Partnering Agreements in Diagnostics includes:
- Trends in diagnostic dealmaking in the biopharma industry since 2000
- Analysis of diagnostic deal structure
- Case studies of real-life diagnostic deals
- Access to over 500 diagnostic contract documents
- The leading diagnostic deals by value since 2000
- Most active diagnostic dealmakers since 2000
- The leading diagnostic partnering resources
In Partnering Agreements in Diagnostics, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Table of Contents

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Overview of diagnostic dealmaking
2.1. Introduction
2.2. The anatomy of diagnostic partnering
2.2.1. The anatomy of an oncology deal
2.2.1.a. Case study 1: Sequenom – Lenetex – January 2007
2.2.1.b. Case study 2: Celera – Siemens Medical Solutions – July 2007
2.2.1.c. Case study 3: US Genomics – Rosetta Genomics – May 2006
2.3. Litigation and settlement in diagnostics

Chapter 3 – Trends in diagnostic dealmaking
3.1. Introduction
3.2. Diagnostic partnering over the years
3.3. Most active diagnostic dealmakers
3.4. Bigpharma diagnostic dealmaking activity
3.5. Bigpharma not active in diagnostics
3.6. Oncology partnering by deal type
3.7. Diagnostic M&A activity since 2000

Chapter 4 – Leading diagnostic deals
4.1. Introduction
4.2. Top diagnostic deals by value
4.3. Top diagnostic involving bigpharma
4.4. Leading diagnostic M&A deals by value

Chapter 5 – Bigpharma diagnostic deals
5.1. Introduction
5.2. How to use bigpharma diagnostic partnering deals
5.3. Bigpharma partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck & Co
Merck – Serono
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Takeda
Teva
UCB
Watson
Wyeth

Chapter 6 – Diagnostic dealmaking directory
6.1. Introduction
6.2. Company A-Z
6.3. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
6.4. By deal type
Asset and product purchase
Collaborative R&D
Co-development
Co-marketing
Co-promotion
Development
Distribution
Joint venture
Licensing
M&A
Manufacturing
Marketing
Promotion
Option
Research
Supply
6.5. By therapy area
Cardiovascular
Central nervous system
Dermatology
Gastrointestinal
Genitourinary
Hematology
Immunology
Infection
Inflammation
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Animal health

Chapter 7 – Diagnostic partnering resource center
7.1. Online diagnostic partnering
7.2. Diagnostic partnering events
7.3. Further reading on diagnostic dealmaking

Appendices

Appendix 1 – Deal type definitions
Appendix 2 – Example diagnostic partnering agreement
About CurrentPartnering
Recent titles from CurrentPartnering

Figures in report

Figure 1: Components of the typical diagnostic deal structure
Figure 2: Settlement licensing agreements since 2003
Figure 3: Diagnostic partnering since 2000
Figure 4: Most active diagnostic dealmakers 2003-2008
Figure 5: Bigpharma – top 50 – diagnostic deals 2003 to 2008
Figure 6: Inactive bigpharma in diagnostic dealmaking 2003-2008
Figure 7: Diagnostic partnering by deal type since 2003
Figure 8: Diagnostic option deals since 2003
Figure 9: Diagnostic partnering by disease type from 2003
Figure 10: Diagnostic M&A since 2000
Figure 11: Top diagnostic deals by value since 2000
Figure 12: Top diagnostic deals signed by bigpharma value since 2000
Figure 13: Top diagnostic M&A deals by value since 2000
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
Figure 17: Diagnostics partnering agreement between Inhibitex and 3M, February 2007